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https://doi.org/10.1016/j.celrep.2021.108738SUMMARYCanonical fatty acid metabolism describes specific enzyme-substrate interactions that result in products
with well-defined chain lengths, degree(s), and positions of unsaturation. Deep profiling of lipids across a
range of prostate cancer cell lines reveals a variety of fatty acids with unusual site(s) of unsaturation that
are not described by canonical pathways. The structure and abundance of these unusual lipids correlate
with changes in desaturase expression and are strong indicators of cellular phenotype. Gene silencing
and stable isotope tracing demonstrate that direct D6 and D8 desaturation of 14:0 (myristic), 16:0 (palmitic),
and 18:0 (stearic) acids by FADS2 generate new families of unsaturated fatty acids (including n-8, n-10, and
n-12) that have rarely—if ever—been reported in human-derived cells. Isomer-resolved lipidomics reveals
the selective incorporation of these unusual fatty acids into complex structural lipids and identifies their
presence in cancer tissues, indicating functional roles in membrane structure and signaling.INTRODUCTION
Fatty acid (FA) metabolism is significantly altered within cancer
cells, with increased FA unsaturation being pivotal in cell trans-
formation, accelerated rates of proliferation, and augmented
invasiveness (Beloribi-Djefaflia et al., 2016; Biswas et al.,
2012; Currie et al., 2013; Röhrig and Schulze, 2016; Schulze
and Harris, 2012; Zadra et al., 2013). The introduction of car-
bon-carbon double bonds (DBs) to specific sites along the FA
chain is catalyzed by three distinct desaturase enzymes and re-
sults in structures with distinct physical properties and cellular
functions (Renne and de Kroon, 2018). Alongside desaturation,
elongation—a process that facilitates a two-carbon-unit chain
extension through the elongase isoforms 1–7 (ELOVL1–7)—
can also have profound effects on FA properties and function
(Guillou et al., 2010). These now-modified FAs are usually
incorporated into various complex lipids, such as phospho-
lipids, whereby molecular properties are imparted to the
functional role of the lipid, e.g., structural membrane packing
(Lorent et al., 2020), fluidity (Scanferlato et al., 2019), and inter-
leaflet interactions (Zhang and Lin, 2019), or specific signalThis is an open access article under the CC BY-Ntransduction (Bratton et al., 1997; Epand, 2017; Hsu et al.,
2013).
Previously, human prostate cancer (PCa) was shown to be
characterized by increased ratios of monosaturated to saturated
FAs relative to normal prostate tissue (Fritz et al., 2010). These
metabolic expressions were supported by transcriptomics
showing elevated mRNA levels for both stearoyl-coenzyme A
(CoA) desaturase-1 (SCD-1) and ELOVL7 (Fritz et al., 2010; Ta-
mura et al., 2009). Others have then focused on discerning the
position of the DB in monounsaturated FAs and found that within
malignant PCa cells, the abundance of FA 18:1n-9 (i.e., an
18-carbon monounsaturated FA with the DB in the 9th position
from the methyl terminus) increases relative to the FA 18:1n-7
isomer compared with non-cancerous prostate cells (Ma et al.,
2016b). Notably, it was recently shown that a secondary desatu-
ration mechanism can be activated to meet the metabolic needs
of cancer (Vriens et al., 2019). The canonical mechanism by
which FAs undergo primary desaturation is through the oxy-
gen-dependent SCD-1 enzyme introducing a DB at the D9 posi-
tion (i.e., the 9th carbon from the FA carboxylate terminus). How-




OPEN ACCESSdesaturase—was also shown to possess primary desaturation
capabilities, catalyzing n-10 DB formation in palmitic acid, which
is a phenomenon usually observed only within lipids from hair
and skin (Nicolaides, 1974). Having two independent mecha-
nisms for primary desaturation creates the opportunity for plas-
ticity in cancer cells, which carries potential functional conse-
quences for membrane structure and signaling.
In order to elucidate if changes in unsaturation are widespread
or confined to specific cellular functions, it is imperative to iden-
tify the unsaturation profiles of complex lipids and not just the FA
building blocks. Unfortunately, technological limitations within
conventional analysis, most notably gas chromatography, first
require FAs to be released from complex lipids by hydrolysis.
The resulting analysis provides a FA profile integrated across
the entire lipid pool, leading to a reduction of molecular-level in-
formation of the lipidome and, moreover, dilution of low abun-
dant FAs that may have a particular association with a specific
lipid class or composition. To overcome these limitations,
next-generation technologies for isomer-resolved lipidomics,
such as Paternò-B€uchi derivatization (Ma et al., 2016a) and
ozone-induced dissociation (OzID); (Paine et al., 2018; Poad
et al., 2010; Thomas et al., 2008), are instead able to discern
DB positions within complex lipids. Such analyses not only pro-
vide links between unsaturation profiles and subcellular location
or function but also create a platform in which lipid DBs can be
imaged directly within a cellular-tissue matrix, revealing spatial
distinctions between enzyme activities.
Here, we use isomer-resolved lipidomics in combination with
small interfering RNA (siRNA) experiments and stable isotope
tracing to reveal substrate promiscuity of the human FA desatur-
ase FADS2. In combination with newly ascribed activity of the
elongase ELOVL2, FADS2 gives rise to multiple FA families,
namely n-8, n-10, and n-12 that have rarely—if ever—been re-
ported in human-derived cells. These experiments also provide
evidence for hitherto apocryphal activity of SCD-1 on 14:0 (myr-
istic acid) and FADS1 modification of 18:0 (stearic acid), giving
the cells access to an expanded repertoire of unsaturated FAs
with n-5 and n-13 DBs. Furthermore, monounsaturated FAs
within these de-novo-synthesized families are revealed as sub-
strates for further desaturation and elongation, yielding a wide
array of polyunsaturated FAs, including an isomer of FA 20:4n-
6 (arachidonic acid), FA 20:4n-7.We demonstrate that theseme-
tabolites display selective and differential incorporation across
different phospholipid classes related to membrane structure
and signaling, which in turn can be used to uncover unique
cellular phenotypes. Moreover, observing the distribution of
these lipids through mass spectrometric tissue imaging im-
proves our understanding of lipidmetabolism in the tumormicro-
environment by revealing distinct enzyme-substrate interactions
in regions of tumor formation.
RESULTS
Widespread remodeling of unsaturation in cellular
lipidomes
In order to explore the impact desaturase and elongase enzymes
have on cellular FAmetabolism, four PCa cell lines frommetasta-
tic deposits (PC-3, LNCaP, DU145, and VCaP; hereinafter2 Cell Reports 34, 108738, February 9, 2021referred to as cancer cells) and two benign immortalized prostate
epithelial cell lines (BPH-1 and RWPE-1; hereafter referred to as
normal prostate cells) were cultured under identical conditions.
Representing the most in-depth lipidomic study of prostate cells
to date, the cells were comprehensively characterized as fol-
lows: by conventional lipidomics to obtain full profiles of molec-
ular phospholipids and neutral lipids (Table S2), allowing com-
parison between phospholipid classes (Figure 1A) and sum
compositions, as shown for the dominant phosphatidylcholine
(PC) class in Figure 1B; by isomer-resolved lipidomics (OzID)
to reveal the contributions of isomers to the populations of
monounsaturated lipid isomers (Tables S4 and S5), as shown
for the most abundant lipid (PC 34:1, Figure 1C); by gas chroma-
tography-mass spectrometry of the saponified extracts yielding
the FA profile integrated over the lipid pool (Table S3); and by
transcriptomics for fatty acyl desaturase expression (Figure 1D).
Data represented in Figures 1A–1C were summarized using an
unsupervised multivariate analysis in the form of principal-
component analysis (PCA) (Figures 1E–1G) to differentiate cell
line profiles.
PCA of the phospholipid profiles (Figure 1E) and the abun-
dance of major PC lipids (Figure 1F) both reveal poor sample
cluster separation, including cluster intermingling, andmixed ad-
equacy in terms of the explanation of variance. This finding is
seen where the phospholipid profile data (Figure 1E) can be
reasonably explained by the first two principal components
(77%), whereas the variation in PC sumcomposition (Figure 1F)
is weakly explained (47%). Combined, these results indicate
that conventional lipidomics contains unexplained factors of
variation that contribute to an inability to distinguish cancer
and normal prostate cell lines. Conversely, PCA of the DB isomer
profiles from major monounsaturated PC species (Figure 1G)
presents independent sample clustering, with the variation being
well captured by the first two principal components (81%). The
clustering of PC-3, LNCaP, and VCaP cancer cell lines also dis-
plays strong negative association across both principal dimen-
sion axes against the normal prostate cell line BPH-1. Overall,
multivariate analysis based on DB profiles clearly distinguishes
between cancer and normal prostate cell lines (Figure 1G),
whereas analogous analyses based on conventional lipidomics
data are unable to do so (Figures 1E and 1F). Differentiation of
cell lines based upon PCA of DB isomers is influenced strongly
by the presence of unusual n-10 lipids. As evidenced in Fig-
ure 1C, PC 34:1n-10 contributions range from being absent in
BPH-1 and VCaP cells to 50% of the isomer fraction in PC-3—
remarkably representing up to 8.5 mol% of total phospholipid
without impacting cell viability.
The high proportion of PC 34:1n-10 in some cell lines (Fig-
ure 1C, green) combined with the significant variation between
unsaturation profiles (Figure 1G) implies change in the SCD-1
and FADS2 enzyme system. Although the delta-delta cycle
threshold (DDCT) mRNA measurements undertaken here inform
of changes to enzyme mRNA transcription (Schmittgen and Li-
vak, 2008), translation to proteins was not measured, and thus,
changes in enzyme activity cannot be distinguished from
enzyme abundance variation. Noting the absence of n-10, the
BPH-1 normal prostate cell line was used as a reference to








Figure 1. Lipid composition and targeted transcripts of normal prostate (BPH-1 and RWPE-1) and cancer (PC-3, LNCaP, DU145, and VCaP)
cell lines
(A) Phospholipid profiles across 6 major classes (PC, sphingomyelin [SM], PE, PS, PG, and PI).
(B) Normalized abundance of major PC lipids quantified at the sum composition level.
(C) Normalized OzID signal intensity from PC 34:1 isomers with double bonds at n-7, n-9, and n-10.
(D) qRT-PCR-derived transcript expression of two desaturases (SCD-1 and FADS2) as a fold-change relative to normal prostate cell (BPH-1) mRNA expression.
(E–G) PCA dimensionality reduction for cell line differentiation based on 6 phospholipid classes (E), sum composition of 10 PCs (F), and double bond isomer
distributions (G) from PC 32:1, 34:1, and 36:1. Ellipses display 95%confidence intervals, with the percentage of data represented by the dimensionality reduction
being displayed as axes.
Data in (A)–(C) are displayed in relative totals for inter-cell line normalization. n = 3, mean ± SEM 95% confidence interval displayed.
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OPEN ACCESSall cell lines. Figure 1D shows a 10-fold increase in the transcrip-
tion of FADS2 for the cancer cell lines PC-3, LNCaP, and DU145,
where the contribution of n-10 unsaturation is most pronounced
(Figure 1C, green). In contrast, RWPE-1 and VCaP cell lines pre-
sent lower transcription of FADS2 (relative to BHP-1) and are
characterized by a decreased abundance and complete
absence, respectively, of the n-10 lipid isomer. Interestingly,
these two cell lines also share a similar transcript expression of
SCD-1 and FADS2 despite the clear difference in PC 34:1 DB
isomer profiles (notably the absence of n-10 in VCaP). This
apparent discrepancy between desaturase transcript expres-
sion and resulting metabolites points to competition between
desaturase enzymes for common substrates with the potential
for additional competition through substrate elongation. Such
competition is also evident across the cell lines in the association
between increased PC 34:1n-10 (Figure 1C, green) and
decreased abundance of PC 34:1n-7 (Figure 1C, purple). Both
isomers share 16:0 as a common substrate, and thus, competi-
tion between the independent SCD-1 or FADS2 reactions is
apparent (Enoch et al., 1976; Ge et al., 2003). Similarly, observing
the VCaP unsaturation profile relative to BPH-1 (Figure 1C), thedecreased presence of PC 34:1n-7 (Figure 1C, purple) is
matched by an increased abundance of PC 34:1n-9 (Figure 1C,
red). As SCD-1 desaturation can yield either n-7 or n-9 FAs de-
pending on the substrate (16:0 or 18:0, respectively), and
ELOVL6 is known to elongate 16:0 to 18:0 (Jakobsson et al.,
2006; Moon et al., 2001), the relative increase of VCaP PC
34:1n-9 suggests competitive 16:0 metabolism by either direct
desaturation or a combination of elongation/desaturation
reactions.
Given the potential for competition between desaturation and
elongation pathways, the association between sites of unsatura-
tion and specific fatty acyl chain length(s) becomes critical for
mapping metabolism. Fatty acyl compositional analysis, based
on collision-induced dissociation (CID) combined with OzID, re-
veals that cell line PC 34:1 is comprised of >95% PC 16:0_18:1
(Table S5), inferring that the vast majority of the n-7, n-9, and
n-10 shown in Figure 1C are carried by 18:1 fatty acyl chains.
Although somewhat varied, fatty acyl compositional analysis
(based on negative polarity CID) of other lipid classes also
revealed a majority contribution of 16:0_18:1 to the 34:1
species of phosphatidylinositol (PI), phosphatidylserine (PS),Cell Reports 34, 108738, February 9, 2021 3
Figure 2. Variation of DBs across the hydrolyzed fatty acyl pool (GC-
MS) and PC, PI, and PG (OzID) complex lipids for normal prostate
BPH-1 cells and PC-3 and LNCaP cancer cells
The 16:0_18:1 fatty acyl composition comprises 95%, 78%, and 96% of total
PC, PI, and PG 34:1 species, respectively. Increased n-10 can be observed
within the cancer cell lines and, in some cases, represents over 50% of the
phospholipid species. Mean values displayed (n = 3).
Article
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OPEN ACCESSphosphatidylethanolamine (PE), and phosphatidylglycerol (PG),
with average contributions of 78%, 58%, 77%, and 96%,
respectively (Table S5). When exploring the DB positions tenta-
tively assigned to the 18:1 chain of these phospholipids, howev-
er, the results show a large perturbation between cancer and
normal prostate cells. Figure 2 displays the fractional contribu-
tions of DB isomers within three lipid subclasses across BPH-1
cells and PC-3 and LNCaP cancer cells. Because the majority
of these monounsaturated lipids carry the 18:1 acyl chain, the
isomer distribution of FA 18:1 from the hydrolyzed lipid pool
was also derived from GC-MS (representative chromatograms
shown in Figure S2).
The results summarized in Figure 2 highlight a significant
contribution of FA 18:1n-10 to the total FA 18:1 pool in PC-3
(32%) and LNCaP (15%) cancer cell lines, whereas it is
completely absent in the BPH-1 normal prostate cells. Any
contribution of FA 18:1n-10 (or FA 16:1n-10; sapienic acid)
from exogenous sources was explicitly excluded by rigorous
analysis of cell culturemedia and other controls (Figure S2; Table
S3). Comparing the isomer factions of FA 18:1 with the major
18:1-bearing lipids (i.e., PC 34:1, PI 34:1, and PG 34:1), two
things become acutely apparent: (1) DB isomer proportions
vary between phospholipid class (i.e., Figure 2, PC versus PI
versus PG), and (2) the PG 34:1 of BPH-1 and PC-3 carries an
additional n-8 isomer. These observations, which would be over-
looked by pooled FA analysis alone, indicate a degree of speci-
ficity in the unsaturation profile across different phospholipid
classes and the potential for greater diversity in lipid unsaturation
than previously considered. Moreover, exploration of the DBs of
triacylglycerols (TGs) and cholesteryl esters (CEs) reveals that
this variation carries into the neutral lipid classes (Table S4).
Remarkably, unusual fatty acyl DB isomers, such as 18:1n-10,4 Cell Reports 34, 108738, February 9, 2021are carried by neutral lipids in cell lines where the same acyl
chain isomers are absent within phospholipid fractions. Consis-
tent with the findings of previous research (Guijas et al., 2016),
the signaling molecule and b-oxidation product of oleic acid
16:1n-9 was also identified in the neutral lipid fractions.
Expanded substrate accommodation of elongase and
desaturase enzymes
Although amajor contributor to the lipid pool for cancer cell lines,
the biosynthetic origin of the FA 18:1n-10 building block remains
to be clarified. The association of 18:1n-10 with the FADS2 desa-
turase is apparent (cf. Figure 1), and the canonical pathway
would proceed by D6-desaturation of 16:0 to 16:1n-10 with sub-
sequent elongation by a hitherto unassigned enzyme. To identify
this elongase (hereinafter referred to as ELOVLx) alongwith other
mechanisms for cancer cell plasticity, the LNCaP cancer cell line
was chosen as a model based on its high expression of FADS2
and n-10 abundance. Cells were subject to gene silencing
by siRNA and enzyme inhibition (Western blot, qRT-PCR, cell
confluence and cell assay titrations in Figure S3) beforemonoun-
saturated phospholipids were characterized by OzID.
Relative to the untreated LNCaP control, the heatmap of Fig-
ure 3A displays DB assignments for 29 monounsaturated phos-
pholipids and their abundance shift in response to treatment with
desaturase gene silencing (siSCD-1 and siFADS2); elongase
gene silencing (siELOVL3, siELOVL6, and siELOVL2); and a
FADS2 inhibitor (SC26196—a potent FADS2 inhibitor that was
found to prevent the conversion of linoleic acid to arachidonic
acid by R95%) (Obukowicz et al., 1998). ELOVL3, ELOVL6,
and ELOVL2 were chosen as they broadly represent canonical
elongation activity for saturated, monounsaturated, and polyun-
saturated fatty acyl substrates, respectively (Green et al., 2010;
Guillou et al., 2010; Jakobsson et al., 2006). Based on previously
established FA modification pathways, Figure S4 lays out the
conceptual implications of preventing enzyme activities. Hori-
zontal cluster grouping in Figure 3A reveals that desaturase
treatments have a similar impact on phospholipids, whereas
elongase treatments are separately grouped. Notably, the
impact siELOVL2 treatment has on phospholipids is distinctive
from that of siELOVL3 and siELOVL6, representing that ELOVL2
has a unique impact on the desaturation and elongation of phos-
pholipid FAs.
Observing the vertical cluster analysis of Figure 3A identifies
two main groups that correspond to SCD-1-related (i.e., pre-
dominately n-7 and n-9) and FADS2-related (i.e., predominately
n-10) lipid products, e.g., PG 32:1n-7 and PG 32:1n-10 display
inverse abundance shifts with the silencing of SCD-1 and
FADS2 and hence are clustered separately. It is important to
note that gene silencing restrict new FA progeny from being
formed but do not remove prior-formed FAs from the cellular
pool. Exchange of FAs between complex lipids, such as between
phospholipids and neutral lipids, could account for the non-intu-
itive responses of some individual phospholipids to silencing
treatments, e.g., increased PG 34:1n-10 abundance with si-
FADS2 and SC26196 treatments and no change in PE 36:1n-9
despite silencing SCD-1. For this reason, trends in unsaturation
and FA chain elongation need to be assessed across the lipid
pool and not restricted to individual species.
A B C
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Figure 3. Enzyme/metabolite correlations and increased enzyme plasticity
(A) Heatmap of treated LNCaP cells showing change in monounsaturated phospholipid DB isomers relative to control (untreated LNCaP). Scale bar indicates fold
change relative to untreated LNCaP control.
(B) Correlation matrix using numeric data from (A) to show positive (blue) and negative (red) correlations (n = 29).
(C) Bivariate analysis, histograms, and correlation matrices for treated LNCaP lipid sum compositional analysis compared with those of control (n = 60). Scale bar
indicates positve/negative correlation coefficient values.
(D) PC 34:1 double bond fractional distribution profile from de novo lipogenisis (left andmid-left),13C16-palmitate tracing with de novo
12C-acyl-CoAmodifications
(mid-right), and 13C18-stearate tracing (right). Lipid structures are displayed above, with
13C-carbons in blue (n = 2, mean ± SEM 95% confidence interval error
bars). Pearson’s correlation with two-tailed t test used for displayed correlation coefficients; *p % 0.05, **p % 0.01, ***p % 0.001.
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rated lipid profiles generated in response to treatments (Fig-
ure 3A), Pearson’s correlation was implemented, and the result-
ing correlation matrix is presented in Figure 3B. Notably, the
inverse relationship between siFADS2 and siSCD-1 identified
previously in Figure 3A is observed in Figure 3B to have statisti-
cally significant negative correlations (p < 0.05 and p < 0.01,
respectively). Similar to the horizontal hierarchical clusters of
Figure 3A, the desaturase and elongase treatments group sepa-
rately at the top and bottom matrix vertices, indicating similarity
in response to like-enzyme treatments. Given the increased
FADS2-related products with siSCD-1 treatment (cf. Figure 3A),
to identify ELOVLx, correlations between siSCD-1 and an
siELOVL treatment are required. Within the matrix region corre-
sponding to the correlation of desaturase treatment profiles
to elongase enzyme treatment profiles, only two statistically
significant positive correlations can be observed between
desaturases and elongases, namely, siSCD-1/siELOVL2 and
SC26196/siELOVL6.As previously mentioned, a canonical activity of ELOVL6 is
elongation of 16:0 to 18:0 (Jakobsson et al., 2006); therefore,
downregulation of this activity by siELOVL6 treatment would
cause accumulation of 16:0, palmitic acid. To prevent palmitic
acid lipotoxicity, canonical activity of SCD-1 would drive desatu-
ration to FA 16:1n-7 (Collins et al., 2010). Likewise, inhibition
of the FADS2 enzyme by SC26196 would prevent palmitic acid
from undergoing FADS2 desaturation to FA 16:1n-10 and
instead consolidate desaturation activity through SCD-1,
creating increases in FA 16:1n-7. These two paths leading to
increased FA 16:1n-7 abundance would in turn present a
positive correlation between siELOVL6 and FADS2 inhibition
(SC26196). The silencing of SCD-1 desaturation (and hence
increased abundance of monounsaturated FADS2 related lipid
products), however, has no reported reason to display positive
correlation to siELOVL2, as ELOVL2 has only been implicated
in polyunsaturated FA elongation. Given that the silencing of
ELOVLx would prevent the elongation of FA 16:1n-10 to FA
18:1n-10, the accumulation FA 16:1n-10 would display positiveCell Reports 34, 108738, February 9, 2021 5
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OPEN ACCESScorrelation with a profile dominated by FADS2-related products,
such aswith siSCD-1. Consistently, this decreased 18:1n-10 for-
mation can be observed within targeted PC 32:1 and PC 34:1 DB
and FA compositions analyses (cf. Figure S6). Therefore, it is
suggested that ELOVL2 is indeed ELOVLx and is responsible
for the elongation of FA 16:1n-10 to FA 18:1n-10.
Akin to themajor role of the FADS2 enzyme in polyunsaturated
lipid synthesis, ELOVL2 has only previously been implicated in
polyunsaturated fatty acyl elongation but never in the elongation
of monounsaturated FAs (Jakobsson et al., 2006; Pauter et al.,
2014). In order to validate the finding that ELOVL2 catalyzes elon-
gation of FA 16:1n-10 to FA 18:1n-10, exploration into the impact
of treatment on thewider lipidomewasconducted.Relative to the
control, Figure 3Cdisplays the correlations between the lipid pro-
files of treatments, consisting of 60 saturated, monounsaturated,
and polyunsaturated sum composition phospholipids (PC, PE,
PS, and PG). As before in Figure 3B, the siELOVL2 and siELOVL6
treatments of Figure 3C display statistically significant positive
correlations to desaturase silencing and inhibition, informing of
moderate-to-high degrees of lipid profile similarity (0.65, p %
0.001 and 0.27, p % 0.05, respectively). Additionally, the profile
from siELOVL6 also shows correlation with the siSCD-1 treat-
ment profile (0.68, p % 0.001). Similar to the logic used previ-
ously, accumulation of 16:0 (palmitic acid) by way of silencing
ELOVL6 would lead to an increase in shorter-chain monounsatu-
rated lipids,which as substrates for further desaturation,would in
turn increase the abundance of polyunsaturated lipids. Compa-
rably, silencing SCD-1 would increase FADS2 activity, which
would increase polyunsaturated lipid abundance due to its major
canonical role in polyunsaturated lipid synthesis. Hence, the pro-
files of siELOVL6 and siSCD-1 would present similarly.
Although slight skewing can be observed, all histograms in
Figure 3C present a normal distribution of the data, with the
exception of siELOVL2. This bimodal distribution suggests that
silencing of ELOVL2 has two distinctive impacts on the lipidome,
which given its known role in the elongation of polyunsaturated
lipids, provides further indication for an additional metabolic
role by ELOVL2. Therefore, the combined data from Figures
3B, 3C, and S6 suggest that ELOVL2 is the most likely candidate
for the unassigned elongase responsible for apocryphal elonga-
tion of 16:1n-10.
To explore the sequence of elongation and desaturation
events, LNCaPcancer cellswere supplementedwith 13C-labeled
FAs. Incorporation of 13C16-palmitate and
13C18-stearate tracers
into PC 13C16-18:1_16:0 (m/z 798) and PC
13C18-18:1_16:0 (m/z
800), respectively, was confirmed by high-resolution tandem
MS (see data archive). The presence of PC 13C16-18:1_16:0
(m/z 798) arising from 13C16-palmitate supplementation indicates
intracellular elongation with installation of two unlabeled carbons
(cf. chemical structures, Figure 3Dii). This conclusion is sup-
ported by OzID of the mass-selected isotopologue that assigns
the location of the two unlabeled methylene units between the
site of unsaturation and the carboxylate moiety (cf. Table S6).
ThePC13C16-18:1_16:0metabolite is also characterizedbyadis-
tribution of sites of unsaturation in the labeled 18:1 chain showing
contributions from n-7, n-9, and n-10 isomers (Figure 3Dii, left). In
contrast, the fully labeledPC13C18-18:1_16:0derived from
13C18-
stearate is characterized by near-exclusive n-9 unsaturation in6 Cell Reports 34, 108738, February 9, 2021the labeled chain (Figure 3Diii, left). These tracer results infer
direct desaturation of stearate giving rise to 18:1n-9, whereas
18:1n-10 follows a desaturation-elongation sequence analogous
to the canonical formation of 18:1n-7. Within the same experi-
mental system, the suppression of n-10 unsaturation in PC
13C16-18:1_16:0 was observed upon the inhibition of FADS2
(SC26196), further demonstrating D6-desaturation of palmitate
prior to elongation (Figure 3Dii, mid). In contrast, inhibition of
the same enzyme in the presence of the 13C18-stearate tracer
yields no observable change to the unsaturation profile of PC
13C18-18:1_16:0 relative to vehicle (Figure 3Diii, mid) and corrob-
orates direct desaturation bySCD-1 to form n-9. For comparison,
the inhibition of SCD-1 (TOFA, originally an ACC1 inhibitor found
to have potent SCD-1 inhibition) (Mason et al., 2012) in the pres-
ence of the 13C16-palmitate tracer led to complete depletion of n-
7 and a significant reduction of n-9 within PC 13C16-18:1_16:0,
indicating the cessation of D9-desaturation of palmitate and
stearate, respectively—an effect that appears to trigger compen-
sation through desaturation by FADS2, yielding an unsaturation
profile dominated by n-10 (Figure 3Dii, right). Such compensation
is also observed when inhibiting SCD-1 in the presence of the
13C18-stearate tracer, which noticeably reduces n-9 unsaturation
within PC 13C18-18:1_16:0 and promotes formation of an unusual
suite of n-13, n-12, and n-10 isomers indicative of directD5-,D6-,
and D8-desaturation of the tracer, respectively (Figure 3Diii,
right).
Given thewell-describedD9-fidelity of SCD-1 (Bai et al., 2015),
these results represent evidence for direct desaturation of stea-
rate by desaturases other than SCD-1. Specifically, the findings
demonstrate that 18:1n-10 can be synthesized directly from
stearate by the hitherto apocryphal D8-desaturation activity of
FADS2. AlthoughD8 desaturases do occur naturally in somema-
rine micro algae (Wallis and Browse, 1999), mammalian D8-de-
saturation of saturated FAs has only been observed exogenously
on skin (Nicolaides, 1974). From the isotope labeling experi-
ments above, the presence of n-12 accompanying n-10 mono-
unsaturation within PC 13C18-18:1_16:0 reveals that FADS2
may also be able to simultaneously exhibit D8-desaturation ac-
tivity alongside canonical D6 activity. This result could indicate
differential activities of the FADS2 enzyme arising from intracel-
lular compartmentalization, local macrostructural environment,
or substrates (i.e., carrier of the stearates). The proclivity of
FADS1 (a third mammalian desaturase) toward D5 activity within
polyunsaturated FAsmay help explain the curious observation of
the n-13 monounsaturated PC 13C18-18:1_16:0. In this instance,
however, the desaturase would require exertion of apocryphal
metabolic behavior to instead act upon saturated substrates
at the D5 position to initiate primary desaturation. This same
D5 motif is observable in Figure 3A, wherein gene silencing of
SCD-1 or FADS2 causes respective amplification or elimination
of an unusual PC 34:1n-11. This variable presence may be
explainable byD5-desaturation of 16:0 (palmitic acid) substrates
by FADS1 during times of lesser competition for substrate by
SCD-1.
Evidence for alternate pathways in lipid desaturation
An analysis of monounsaturated phospholipids within PCa




Figure 4. Pooled fatty acyl quantitation and
double bond analysis of normal prostate cells
(BPH-1), cancer cells (PC-3), and gene
silencing of desaturases in cancer cells
(LNCaP)
(A) Cell-count-normalized quantitative sum compo-
sition fatty acyl analysis with magnification insert
(n = 3; mean ± SEM 95% confidence interval error;
two-tailedWelch’s t test used for p values: *p% 0.05,
**p% 0.01, ***p% 0.005).
(B) Fractional distribution profiles for 15 mono- and
polyunsaturated fatty acids from the hydrolyzed
lipid pool (n = 3; mean fractional distribution dis-
played).
(C) Heatmap of treated LNCaP cells showing
change in mono- and polyunsaturated fatty acid
isomers from the hydrolyzed lipid pool (relative to
LNCaP control). Scale bar indicates fold change
relative to untreated LNCaP control. Annotated
mass spectra of the unusual AMPP 20:4 species




OPEN ACCESS(vide supra). To visualize this diversity across the entire fatty acyl
pool, cell line extracts were hydrolyzed, derivatized with 1-[4-
(aminomethyl)phenyl] pyridinium (AMPP+), and subjected to
OzID. This direct-infusion MS approach was found to be more
sensitive to low-abundant FAs and enabled unambiguous
assignment of positions in the absence of reference standards
(Poad et al., 2019). Comparison of AMPP+ against GC-MS re-
sults can be found in Figure S2. Figure 4A displays molar abun-
dance of sum composition FAs for the two representative cell
lines PC-3 (cancer) and BPH-1 (normal prostate) across three or-
ders of magnitude. When isomeric contributions are ignored, the
abundance of the saturated and monounsaturated FAs are well
conserved between cell lines. In contrast, several low-abundant
polyunsaturated FAs show significant changes in cellular abun-
dances, e.g., FA 20:3, FA 20:4, and FA 22:6 are more abundant
in PC-3 than in BPH-1.
As was observed within phospholipids, ostensibly similar sum
composition profiles can mask significant isomeric differences
(cf. Figure 1; Table S2). Fatty acyl isomer profiles were thus ex-
tracted from OzID analysis and are presented in Figure 4B.
Among themonounsaturated even-chain FAs of PC-3, the apoc-
ryphal elongation of FA 16:1n-10 to FA 18:1n-10 that has been
shown throughout appears not to be a terminal step in the elon-
gation of the n-10 family. Instead, this family includes longer-chain FAs, such as 20:1, 22:1, and 24:1,
representing successive chain elongation
(vide infra Figure 5vi). Alongside further
elongation of FA 18:1n-10 substrates, the
presence of FA 18:2n-10, the skin lipid se-
baleic acid, indicates the possibility for
additional desaturation using this same
FA 18:1 substrate and demonstrates a
point of divergence in enzymatic activity
surrounding the FA 18:1n-10. Further com-
binations of elongation and desaturation of
FA 18:2n-10 subsequently lead to addi-tional n-10 polyunsaturated fatty acyl species observed within
FA 20:2, FA 22:2, and FA 22:3 (Figure 4B; vide infra Figure 5vii).
A similar enzyme branch point can be observed with FA 18:1n-
7, whereby the presence of n-7 isomers within FA 20:1, FA
22:1, and FA 24:1 (vide infra Figure 5iv) indicates elongation,
whereas n-7 contributions to polyunsaturated FA 18:2, FA
20:2, FA 20:3, FA 20:4, and FA 22:4 demonstrate competitive
elongation and desaturation (Figure 4B; vide infra Figure 5iv).
These polyunsaturated FAs identified in PC-3 (and LNCaP; cf.
Table S4) are remarkable not only because their biosynthetic or-
igins and DB modifications are achieved solely through cellular
mechanisms but also because they bear structural similarity to
dietary-derived, biologically active FAs, such as arachidonic
acid and adrenic acid.
The multiple isomeric species observed within the FA 20:4
profile of PC-3 in Figure 4B, including FA 20:4n-7, an isomer
also seen within PI 38:4n-7 of PCa tissues and cell lines (cf. Fig-
ure 6C), and their absence from normal prostate BPH-1 cells
represent an overall increase in the isomer diversity of polyunsat-
urated FAs in PC-3 and other cancer cell lines (cf. Table S4). This
increased isomeric complexity of polyunsaturated fatty acyl pro-
files appears to correspondwith an increase in isomer speciation
created during the primary desaturation of shorter-chain satu-
rated FAs (i.e., FA 14:0, FA 16:0, and FA 18:0) and can be clearlyCell Reports 34, 108738, February 9, 2021 7
Figure 5. Fatty acyl desaturase and elongase pathways rationalizing the fatty acyl species observed within this study
Gray shading shows previously defined pathways (Guillou et al., 2010), and colored pathways show unusual FA species found in human prostate cell lines. Gray
text represents known possibilities for mammalian enzyme activity, green text shows confirmed enzyme results for human prostate cell lines, and orange text
displays enzymes requiring further confirmation.
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OPEN ACCESSobserved with desaturase gene silencing (Figure 4C). Relative to
the untreated LNCaP control, gene silencing of cellular FADS2
decreases the isomeric complexity of monounsaturated FA
14:1, FA 16:1, and FA 18:1 by heavily reducing the presence of
n-8, n-10, and n-12 isomers while simultaneously eliminating of
FA 20:4n-7 and consolidating the FA 20:4 profile in FA 20:4n-6,
arachidonic acid. Conversely, the FA profile from SCD-1 gene
silencing appears to have greater isomeric speciation within FA
14:1, FA 16:1, and FA 18:1, which in turn has no impact on poly-
unsaturated FA 20:4 isomer complexity, as both FA 20:4n-7 and
FA 20:4n-6 are found to be present.
The expanded isomeric complexity afforded by apocryphal
primary desaturation also creates an array of unusual monoun-
saturated FAs, which individually infer explicit enzyme-substrate
activity that can be organized into a network of metabolites (Fig-
ure 5). For example, FA 24:1n-5, which is present in the FAs of
PC-3 in Figure 4B, is consistent with canonical SCD-1 D9-desa-
turation of FA 14:0 to initially yield FA 14:1n-5 along with
other chain length intermediates in this n-5 family (Figure 5i;
Table S4). In another example of divergent enzyme action, this
same FA 14:0 substrate is seen to undergo D6-desaturation by
FADS2 to form FA 14:1n-8, a product that is observed within
PC-3 (Figure 4B) and is highly sensitive to gene silencing of
FADS2 (Figure 4C). The presence of this DB position in various
chain lengths (see Table S4) indicates that this family of FAs
has the ability to extend to at least FA 24:1 (Figure 5ii) and has8 Cell Reports 34, 108738, February 9, 2021the potential for incorporation into intact phospholipids (cf. Fig-
ure 2). Shifting to FA 18:0 as a substrate, FADS2D6-desaturation
yields FA 18:1n-12, which along with the 20:1, 22:1, and 24:1, is a
FA family that can be observed in the FAs of PC-3 (Figures 4B
and 5iix). The 18:1n-12, is also seen to form under SCD-1 inhibi-
tion of intact lipids with incorporated heavy-labeled FAs (cf. Fig-
ure 3D) and shows sensitivity to FADS2 gene silencing with
apparent decreases relative to the control (Figure 4C).
Seemingly beyond the reportedD9 andD6 positional activities
for primary desaturation by SCD-1 or FADS2, two additional
monounsaturated FA families can be observed in Figures 4B
and 4C, namely, n-11 and n-13 (cf. Figures 3A and 3D). The
emergence of both of these families is consistent withD5 primary
desaturation of either FA 16:0 or FA 18:0 substrates to initially
yield FA 16:1n-11 and FA 18:1n-13, respectively, before chain
elongation with intermediates observed out to FA 24:1 (cf. Table
S4; Figures 5iii and 5ix). Although no mammalian desaturase
has been reported to facilitate D5 primary desaturation for
the synthesis of monounsaturated FAs, D5-desaturation is
commonplace during the synthesis of polyunsaturated FAs
and undertaken by FADS1. Notably, both FADS1 and FADS2
are genetically coded by the same region on chromosome
11q12-q13.1 and share remarkable similarity in their exon/intron
structure and nucleotide position for boundary disruption and a
high degree of polypeptide sequence identity (Marquardt et al.,
2000). This same region has been associated with single-
A
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Figure 6. Metabolic differentiation of tumor in human prostate tissue
(A) Two separate patient prostate lobe sections showing (left to right) MALDI-MSI-OzID distribution of PC 34:1n-9 (yellow), PC 34:1n-7 (magenta), and PC 36:4n-6
(cyan); a composite image of these lipids; and the adjacent tissue section H&E stained. Magnification of tumor regions is shown; full images and spectral
comparisons are found in Figure S1.
(B) False-positive n-10 signal arising from n-9 standards (gray) compared with tissue lipid extracts from both prostate lobes of 8 patients (n = 16); comparisons
include PS 36:1n-10 (red), PE 34:1n-10 (blue), PE 36:1n-10 (orange), and PC 34:1n-10 (green).
(C) n-7 Signal arising from PI 38:4n-6 standard (gray/red line marker), four PCa cell lines (white), and tissue lipid extracts from both prostate lobes of 8 patients
(n = 16; gold). The p values compare biologically occurring PI 38:4n-7 against false-positive n-7 signal from synthetic PI 38:4n-6 standard (red line marker). Scale
bar: 2.60 mm. nR 3 (standards), n = 3 (cell lines), and n = 16 (tissues); one-tailed Welch’s t-test used for p values: **p% 0.01, ***p% 0.005, and ****p% 0.0001.
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OPEN ACCESSnucleotide polymorphisms, DNA methylation, and alternate
splicing—features that are known to alter the expression and
translation of DNA (He et al., 2018; Park et al., 2012). Given the
evidence (1) that FADS2 has the ability to exhibit high degrees
of plasticity, (2) that the DNA within chromosome 11q12-q13.1
has the propensity to undergo changes, (3) of the gene sequence
similarity between FADS1 and FASDS2, and (iv) of prior estab-
lished changes to FADS1 activity (Park et al., 2018), it is specu-
lated that, similar to FADS2, FADS1 is exhibiting plasticity by
apocryphal D5 primary desaturation to form both n-11 and n-
13 FA families.
Lipid unsaturation profiles in human prostate tissue
Lipid unsaturation distributions in human prostate sections were
mapped using OzID coupled with matrix-assisted laser desorp-
tion ionisation MS imaging (MALDI-MSI). Figure 6A presents a
spatial distribution between the monounsaturated phosphatidyl-
choline isomers PC 34:1n-9 (yellow) and PC 34:1n-7 (magenta),
which are both metabolites of SCD-1, and the polyunsaturated
PC 36:4n-6 (cyan), a metabolite formed through dietary FA sub-
strates and FADS2 interactions. Comparison to the hematoxylin
and eosin (H&E) stains of adjacent tissue sections reveals an in-crease of PC 34:1n-9 and a corresponding decrease of PC
36:4n-6 specific to the tumorous regions of the tissue. As these
two metabolites are representative of two different desaturase
enzyme activities, they are indicative of a change in substrate-
enzyme interactions between tumor and adjacent non-tumor
cells. The twoPC34:1 isomers are also found to have distinct dis-
tributions (Figure 6A). In this instance, however, both n-7 and n-9
forms arise from SCD-1 activity but differ by starting substrate,
requiring either FA 16:0 or FA 18:0, respectively. In some regions
across the tissue, signals consistent with a third DB isomer, the
FADS2metabolite PC 34:1n-10, were detected, but abundances
were insufficient tomapdistribution.Challenges in characterizing
less abundant metabolites are inherent to the MALDI-MSI tech-
nique (due to small sampling volumes), and therefore, to increase
the signal, lipids were extracted from homogenized PCa tissues
and subjected to direct infusion electrospray ionisation (ESI)-
OzID analysis. Examination of lipid standards under identical
conditions provided benchmarks for false-positive signals, thus
confirming the presence of PC 34:1n-10 at low abundance in
PCa tissues (Figure 6B, green). Analogous DB analysis of
selected monounsaturated PS and PE lipids also unveiled them
as carriers of the unusual n-10 isomer within PS 36:1 and PECell Reports 34, 108738, February 9, 2021 9
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OPEN ACCESS36:1 (Figure 6B, red and orange). Interestingly, signals arising
from PE 34:1n-10 (blue) were insignificantly differentiated from
background, indicating that incorporation of the n-10 FA may
vary between lipid class and composition.
Examination of profiles from polyunsaturated lipids in PCa tis-
sue extracts revealed that a previously unreported n-7 isomer
was present alongside the highly active signaling lipid, PI
38:4n-6 (Epand, 2017). The use of high-resolution MS and
OzID allowed for the unambiguous assignment of PI 38:4n-7
(cf. Figure S5; Table S6). The ratio of signals arising from this lipid
and the canonical PI 38:4n-6 are displayed in Figure 6C, which
reveals that tissue and PCa cell line extracts display PI 38:4n-7
around 10%–15% above any background signal arising from
the n-6 synthetic standard. Further evidence for apocryphal de-
saturation in PI 38:4 was obtained by comparison to (and be-
tween) PCa cell line lipid extracts (Figure 6C) and PCa cell line
fatty acyl DB analysis (Figure 4B). These findings present the ex-
istence of the n-10 monounsaturated FAs and n-7 polyunsatu-
rated FA within human primary prostate tumors. This finding
implies changes to desaturase enzyme activity or expression
across tumor tissues, which, in turn, impacts lipids associated
with intracellular membrane structures and signals (Bratton
et al., 1997; Cocco et al., 2015; Williams et al., 2011).
DISCUSSION
Origin and consequence of desaturation plasticity
Exploration of FA DBs within cancer cell lipids in combination
with gene silencing and isotope tracing experiments has re-
vealed that mammalian cellular fatty acyl modification is far
more dynamic than previously considered. It is important to
note that the flow chart represented in Figure 5 presents the
metabolic capabilities of mammalian cells, with some FA fam-
ilies arising due to extreme metabolic stress (e.g., SCD-1
gene silencing allowing FADS1 n-13 formation). Because can-
cer is known to be severely disruptive to cellular fatty acyl
metabolism, however, it stands to reason that this expanded
network of possibilities for FA modification provides plasticity
for changes to lipid uptake or FA enzyme expression in PCa
cells and tumor tissue.
Although SCD-1 and FADS2 largely show preference for ca-
nonical D9 and D6 sites during primary desaturation, a change
in substrate availability and/or enzyme expression can coax a
plastic response from the FADS2 enzyme—potentially yielding
a much wider array of mono- and polyunsaturated FA isomers.
For example, relative to the normal prostate BPH-1 cells, PC-3
cancer cells display a significant change in expression of
SCD-1 and FADS2 (cf. Figure 1D), which in turn has a large
downstream effect on the isomeric complexity expressed within
the mono- and polyunsaturated FAs of PC-3 compared with that
of BPH-1 (cf. Figure 4B). Furthermore, if substrate availability is
altered in combination with these enzyme expression/activity
differences, FADS2 (and possibly FADS1) plasticity allows for
substrate acceptance usually observed in sebocytes (e.g.,
FADS2 D6-desaturation of 14:0, 16:0, and 18:0 to yield n-8,
n-10, and n-12, respectively) or even changes to the enzyme-
substrate complex to result in an alternative site of desaturation
(e.g., FADS2 D8-desaturation of 18:0 to yield 18:1n-10). The10 Cell Reports 34, 108738, February 9, 2021metabolic similarity to sebum is an interesting point to ponder;
sebum only contains these unusual FADS2 metabolites because
sebocytes lack the expression of SCD-1 (Ge et al., 2003). One
reason for this may be because SCD-1 desaturation is an oxy-
gen-dependent reaction, meaning the oxygen-independent
FADS2 can more finely regulate desaturation reactions for lipid
homeostasis in the oxygen-rich environment of the skin. Given
the hypoxic conditions of some tumorous tissues, it is logical
to think that the SCD-1 reaction would become limited (Röhrig
and Schulze, 2016) and thereby cause the upregulation of
FADS2 to allow adoption of primary desaturation behaviors
alongside its role in polyunsaturation events. This would account
for the increase in FADS2 expression seen in the transcripts of
cancer cell lines (Figure 1D), the unusual desaturation products
observed (Figures 1C and 4B), and the increase in polyunsatu-
rated FA products observed (Figure 4A). Similarly, under meta-
bolic stress, SCD-1 and FADS1 also displayed plasticity toward
substrate preference to allow for the formation of n-5, n-11, and
n-13 FA families, further demonstrating cancer’s propensity to
adapt.
As has been shown in previous studies into cancer and
normal prostate cell lines, a strong distinction is created when
observing the differences of FA 18:1 DB isomers from the hy-
drolyzed FA pool (Ma et al., 2016b). These differences pertain
to a change in either substrate availability or substrate prefer-
ence by the SCD-1 enzyme, which in turn causes a statistically
significant increase of the FA 18:1n-9 isomeric fraction (relative
to the FA 18:1n-7) within cancer cells. More recently, in a study
of human breast cancer and adjacent non-tumorous tissues, it
was shown that a small number of sum composition phospho-
lipids displayed a minor but statistically significant change in
abundance (Wenpeng et al., 2019). The authors were then
able to show that (1) discerning the DB location greatly
increased the significance of the phenotypic distinction and
(2) the phospholipids from cancer tissues contained a much
higher proportion of the 18:1n-9 fatty acyl chain than the
18:1n-7. Here, we were able to show that the elucidation of
DB positions in the context of complex lipids served to further
improve phenotypic distinction while simultaneously providing
a rich fingerprint for metabolic activity in PCa tissues. Further-
more, similar to the findings in breast cancer tissue, we were
able to show that epithelial cancer cells in prostate tissue also
contained higher proportions of n-9 in PC 34:1 (cf. Figure 6A).
This feature of aberrant SCD-1 behavior, however, was also
marked by the absence of usual FADS2 polyunsaturated FA
metabolites and perhaps indicates FADS2 plasticity with a
change toward primary desaturation. The n-10 FA metabolites
associated with this enzyme plasticity were not observed in
the imaging of PC 34:1 but instead were found in other phos-
pholipid classes, suggesting that, similar to PCa cell lines, these
unusual FAs are unevenly distributed among phospholipid sub-
classes. n-10 Phospholipids and other metabolites generated
by FADS2 plasticity were detected in all clinical prostate spec-
imens; however, no linear relationship was observed between
the presence of n-10 phospholipids and percentage tumor con-
tent. As all tissues examined (Figures 6A and 6C) were derived
from radical prostatectomy specimens containing PCa, it is not
possible to disentangle if unusual FADS2 activity is a general
Article
ll
OPEN ACCESSfeature of prostate epithelial cells or specific to unhealthy (i.e.,
cancer, field-cancerization, or premalignant aberrations in his-
tologically benign tissue) prostate cell function. Further experi-
mentation and comparison to tumor-free prostate tissue derived
from healthy prostate (obtained at cystoprostatectomy) and
benign prostatic hyperplasia will provide further insight into
this distinction and hence clinical utility.
From cell line studies, we were able to reveal that all FA me-
tabolites formed from apocryphal desaturation activity were
active substrates for elongation, and ELOVL2 was shown as a
candidate in further diversifying the n-10 family. This finding is
perhaps an ode to the canonical role of ELOVL2 in elongating
FADS2-modified dietary fatty acyl metabolites (Guillou et al.,
2010), which may suggest co-localization or co-activity between
enzymes. Instead of these unusual FA metabolites being re-
garded by cellular machinery as malformed or unusable, they
are functionalized through incorporation into known membrane
and signaling phospholipid classes. As further indication toward
a functional role, these unusual FA metabolites are found to be
unevenly associated with certain phospholipid subclasses
compared to others (cf. Figure 2; Table S4). Given that DB loca-
tion will modulate inter-molecular forces and thus membrane
properties (Lorent et al., 2020; Renne and de Kroon, 2018;
Scanferlato et al., 2019), here it is speculated that the different
isomer profiles of each phospholipid class will promote distinc-
tive membrane fluidities among the organelles. Interestingly,
activation of mTOR promotes FADS2 expression (Triki et al.,
2020), opening the possibility that these systems may work
together to tune lipid isomer populations to assist proliferation
and resist apoptosis. For example, changes in membrane
fluidity could promote mitosis for cancer cell stemness (Li
et al., 2017) or hinder apoptosis triggered by PS outer-leaflet
exposure (Bratton et al., 1997) or ferroptosis (Tousignant et al.,
2020). Similarly, the synthesis of entirely de-novo-synthesized
polyunsaturated FAs, such as FA 20:4n-7, bear remarkable sim-
ilarity to biologically active FA metabolites and are being incor-
porated into known signaling phospholipids. Consequently,
this may disrupt homeostatic lipid signaling or, indeed, fulfill
usual signaling roles in the absence of dietary FA uptake or
other chemical environment changes. Although further work is
required to specify the biological impact that unusual lipid unsa-
turation has on cells, the experimental workflows and findings
presented throughout this body of work serve as a roadmap
toward future discovery.STAR+METHODS
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Enoch, H.G., Catalá, A., and Strittmatter, P. (1976). Mechanism of rat liver
microsomal stearyl-CoA desaturase. Studies of the substrate specificity,
enzyme-substrate interactions, and the function of lipid. J. Biol. Chem. 251,
5095–5103.
Epand, R.M. (2017). Features of the Phosphatidylinositol Cycle and its Role in
Signal Transduction. J. Membr. Biol. 250, 353–366.
Fahy, E., Subramaniam, S., Murphy, R.C., Nishijima, M., Raetz, C.R.H., Shi-
mizu, T., Spener, F., van Meer, G., Wakelam, M.J.O., and Dennis, E.A.
(2009). Update of the LIPID MAPS comprehensive classification system for
lipids. J. Lipid Res. 50, S9–S14.
Fritz, V., Benfodda, Z., Rodier, G., Henriquet, C., Iborra, F., Avancès, C., Allory,
Y., de la Taille, A., Culine, S., Blancou, H., et al. (2010). Abrogation of de novo
lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic
signaling and blocks prostate cancer progression inmice. Mol. Cancer Ther. 9,
1740–1754.
Ge, L., Gordon, J.S., Hsuan, C., Stenn, K., and Prouty, S.M. (2003). Identifica-
tion of the delta-6 desaturase of human sebaceous glands: expression and
enzyme activity. J. Invest. Dermatol. 120, 707–714.
Green, C.D., Ozguden-Akkoc, C.G., Wang, Y., Jump, D.B., and Olson, L.K.
(2010). Role of fatty acid elongases in determination of de novo synthesized
monounsaturated fatty acid species. J. Lipid Res. 51, 1871–1877.
Guijas, C., Meana, C., Astudillo, A.M., Balboa, M.A., and Balsinde, J. (2016).
Foamy Monocytes Are Enriched in cis-7-Hexadecenoic Fatty Acid (16:1n-9),
a Possible Biomarker for Early Detection of Cardiovascular Disease. Cell
Chem. Biol. 23, 689–699.
Guillou, H., Zadravec, D., Martin, P.G.P., and Jacobsson, A. (2010). The key
roles of elongases and desaturases in mammalian fatty acid metabolism:
Insights from transgenic mice. Prog. Lipid Res. 49, 186–199.12 Cell Reports 34, 108738, February 9, 2021Hancock, S.E., Maccarone, A.T., Poad, B.L.J., Trevitt, A.J., Mitchell, T.W., and
Blanksby, S.J. (2019). Reaction of ionised steryl esters with ozone in the gas
phase. Chem. Phys. Lipids 221, 198–206.
He, Z., Zhang, R., Jiang, F., Zhang, H., Zhao, A., Xu, B., Jin, L., Wang, T., Jia,
W., Jia, W., and Hu, C. (2018). FADS1-FADS2 genetic polymorphisms are
associated with fatty acid metabolism through changes in DNA methylation
and gene expression. Clin. Epigenetics 10, 113.
Hsu, L.-C., Wen, Z.-H., Chen, H.-M., Lin, H.-T., Chiu, C.-M., and Wu, H.-C.
(2013). Evaluation of the Anti-Inflammatory Activities of 5,8,11-cis-Eicosatrie-
noic Acid. Food Sci. Nutr. 04, 113–119.
Jakobsson, A., Westerberg, R., and Jacobsson, A. (2006). Fatty acid elon-
gases in mammals: their regulation and roles in metabolism. Prog. Lipid Res.
45, 237–249.
Li, J., Condello, S., Thomes-Pepin, J., Ma, X., Xia, Y., Hurley, T.D., Matei, D.,
and Cheng, J.-X. (2017). Lipid Desaturation Is a Metabolic Marker and Thera-
peutic Target of Ovarian Cancer Stem Cells. Cell Stem Cell 20, 303–314.e5.
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Sodium orthovanadate 99.99% Sigma-Aldrich Cat. # 450243
Sodium pyrophosphate 99% (BioUltra) Sigma-Aldrich Cat. # 71501
b-glycerophosphate Sigma-Aldrich Cat. # G9422
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RNEasy mini kit QIAGEN Cat. # 74104
SensiFast cDNA synthesis kit Bioline Cat. # BIO-65053
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Collection (ATCC)
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FADS2 Sigma-Aldrich SASI_Hs01_00029610, SASI_Hs01_00029612,
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Other
CM 1950 Cryostat Leica Biosystems N/A
Glass slides (SuperFrost plus) Menzel-Gläser Thermo Scientific Cat. # 4951PLUS4
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The datasets generated during and/or analyzed during the current study are available as a data archive from QUT Research Data
Finder using the following DOI: https://doi.org/10.25912/RDF_1611708145189
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human tissues
Prostate tissues were collected with ethical approval of the St. Vincent’s Hospital Human Ethics Committee and in accordance with
Australian National Health and Medical Research Council Guidelines. Tissues samples were collected from radical prostatectomy
specimens by a pathologist, immediately snap frozen in liquid nitrogen, and stored at80C. Both right and left lobes were collected
from adult human-males. Age is not reported as samples were deidentified and are not linked to any donor information.
Cell culturing
LNCaP (RRID: CVCL_0395), VCaP (RRID: CVCL_2235), PC-3 (RRID: CVCL_0035), DU145 (RRID: CVCL_0105) and RWPE-1 (RRID:
CVCL_3791) cells were obtained from the American Type Cell Culture Collection (ATCC; Manassas, Virginia, USA), while BPH-1
(RRID: CVCL_1091) was gifted by P. J. Russell and J. Clements (Australian Prostate Cancer Centre-Queensland, Australia). All
cell lines were cultured in Roswell Park Memorial Institute (RPMI) medium (Thermo Fisher, Waltham, MA, USA) supplemented
with 5% fetal bovine serum (FBS, Invitrogen, Waltham, MA, USA) and incubated at 37C in 5% CO2. Medium was changed every
3 days, and cells were passaged at approximately 80% confluency by trypsinisation. Cell lines were authenticated using genotyping
in March 2018 by Genomics Research Centre (Brisbane, Australia) and routinely tested to exclude mycoplasma infection. Cell num-
ber and viability was determined by trypan blue staining and using a TC20 Automated Cell Counter (Bio-Rad).
METHOD DETAILS
Lipid nomenclature
Lipid nomenclature was based on previously defined shorthand naming systems that only state the level of molecular detail that is
known (Fahy et al., 2009; Liebisch et al., 2013). In short, the lipid category is defined by a two-letter abbreviation (e.g., PC; phospha-
tidylcholine) followed by the number of carbons andDBs in the fatty acids separated by a colon (e.g., a PCwith 34 carbons and 2DBs;
PC 34:2). If further analysis has been undertaken to reveal individual fatty acid composition but not the stereospecific number on the
glycerol backbone (i.e., sn-position), this can be indicated with an underscore (i.e., PC 16:0_18:2). Instead, if sn-position is known
fatty acids can be separated by a forward-slash (i.e., sn-1/sn-2; PC 16:0/18:2). For established positions, the digit indicating the num-
ber of DBs is directly followed by the n-number when referencing the number of carbons distal to the methyl terminus (i.e., PC 16:0/
18:2n-6) or the bracketed D-number when referencing the carboxylate terminus (i.e., PC 16:0/18:2(D9)). It should be noted that a sin-
gle position given in polyunsaturated series impliesmethylene interruption of subsequent DBs (i.e., PC 16:0/18:2n-6 = PC 16:0/18:2n-
6,9). A table of fatty acyl common names and shorthand nomenclature equivalents is provided in Table S1.
Tissue sectioning and mounting
Using a CM 1950 Cryostat (Leica Biosystems, Nussloch, Germany), tissue biopsies were sectioned at 10 mm thickness using a blade
that was free from optimal cutting temperature (OCT) compound and fixed on standard glass slides (SuperFrost +, Menzel-Gläser,
Braunschweig, Germany) using 10% neutral buffered formalin for 30 s prior toMALDI-MS imaging protocol (refer to method ‘‘MALDI-
MSI OzID for lipid double bond imaging’’) and the hematoxylin and eosin (H&E) staining protocol (refer to method ‘‘Haematoxylin and
Eosin Staining’’). Tissue slides for MALDI-MSI were placed into a sealed slide holder and purged with nitrogen gas before being
stored on dry ice for inter-laboratory shipping.
Haematoxylin and Eosin Staining
Tissue H&E staining took place after sectioning/mounting using an autostainer (Tissue-Tek Prisma, Sakura Finetek, Torrance, CA,
USA) according to the following sequence: tissues were washed with water for 2 minutes before being exposed to hematoxylin
(Harris Haematoxylin (PAH), Australian Biostain P/L, Traralgon, Australia) for 5 minutes. ‘‘Bluing’’ was achieved with water rinsing
for 4 minutes and exposed for 10 s to ethanol (Chem Supply Gilman, Australia) acidified with 1% HCl before 5 minutes of further
rinsing with water. Eosin staining (0.25% Eosin Y; certified C.C. # 45380, ProSciTech, Kirwan, Australia) took place for 2 minutes
before 40 s of water rinsing. One 80% ethanol rinse followed by two 100% ethanol rinses then took place for 45 s, 30 s and 45 s,
respectively. Triplicate xylene (Point Of Care Diagnostics, North Rock, Australia) washes were then conducted for 1 minute each.
Coverslips (Tissue-Tek Glas, Sakura Finetek, Torrance, CA, USA) were then applied before imaging using a Pannoramic Digital slide
scanner (3DHistech, Hungary) for histopathological analyses.
Gene silencing by siRNA and enzyme inhibition
LNCaP cells were seeded at 1.2x105 cells/well in 6-well plates. After 48 hours, cells were transfected with 10 nM siRNAs (Sigma-
Aldrich) targeting SCD-1 (SASI_Hs01_00029617, SASI_Hs01_00181377, SASI_Hs01_00181371), FADS2 (SASI_Hs01_00029610,Cell Reports 34, 108738, February 9, 2021 e4
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OPEN ACCESSSASI_Hs01_00029612, SASI_Hs01_00029608), ELOV2 (SASI_Hs01_00018935), ELOVL3 (SASI_Hs01_00086480), and ELOVL6
(SASI_Hs01_00242071). Off-target effects were controlled using a scrambled siRNA control sequence (SIC001, Sigma-Aldrich)
at 10 nM. Before forward transfection, growth medium was replaced with 1 mL serum free medium (RPMI 1640), and transfection
solution using RNAiMAX lipofectamine reagent was prepared according to the manufacturer’s instructions (Thermo Fisher).
Following six hours of transfection, FBS was added to the medium to a final concentration of 5%, and cells were grown for 72 hours.
For direct inhibition of enzyme activity, 2 million cells were treated for 72 hours with the indicated concentrations of SC26196
(FADS2D6 inhibitor, 30 mM in DMSO, Sigma-Aldrich) and 5-tetradecyloxy-2-furoic acid (TOFA; combination SCD-1D9 /ACC1 inhib-
itor, 5 mM in DMSO, Sigma-Aldrich). Cell assay titrations for inhibitor concentrations can be found in Figure S3.
13Carbon tracing
For 13C tracing studies, LNCaP cells were chosen due to their heightened FADS2 expression. Cells were seeded and cultured under
the conditions mentioned previously (refer to experimental model ‘‘Cell culturing’’). After 48 hours of seeding, cells were switched to
fresh media supplemented with either unlabeled (i.e., 12C16-palmitic acid) or labeled (i.e.,
13C16-palmitic acid or
13C18-stearic acid)
fatty acids conjugated to bovine serum albumin (BSA) at a final concentration of 20 mM. All fatty acids were purchased from Sigma
Aldrich, Castle Hill, Australia. Cells were grown for a further 72 hours andwashed twice with ice-cold phosphate buffered saline (PBS)
before lipid extraction.
RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR)
Cells seeded in 6 well plates were grown in 5% FBS to a confluency of 70% before RNA extraction using the RNEasy mini kit
(QIAGEN, Hilden, Germany) following the manufacturer’s instructions. RNA concentration was measured using a NanoDrop ND-
1000 Spectrophotometer (Thermo Scientific, Waltham, MA, USA). 2 mg of total RNA was used to prepare cDNA with SensiFast
cDNA synthesis kit (Bioline) according to the manufacturer’s instructions and diluted 1:6 with DNase/RNase-free water (Thermo
Fisher, Waltham, MA, USA). qRT-PCR was performed with SYBR-Green Master Mix (Thermo Fisher Scientific, Waltham, MA,
USA) using the ViiA-7 Real-Time PCR system (Applied Biosystems, Forster City, CA, USA). Determination of relative mRNA levels
was calculated using the comparative DDCt method (Schmittgen and Livak, 2008), where expression levels were normalized relative
to that of the housekeeping gene receptor-like protein 32 (RPL32) for each treatment and calculated as fold change relative to
the expression levels of BPH-1 cells. All experiments were performed in triplicate and analysis and statistics were performed with
Microsoft Excel. Primer sequences can be found in in the Key resources table).
Western blot confirmation method
Cell seeding and gene silencing of FADS2 was carried out as described above. Protein extracts for western blotting were generated
from whole cell lysates prepared in lysis buffer [50 mM Tris, HCl pH 7.6, 150 mM sodium chloride, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, one cOmplete EDTA-free Protease Inhibitor Cocktail tablet (Roche) per 10 mL, phosphatase inhibitors so-
dium fluoride (30 mM), sodium pyrophosphate (20 mM), b-glycerophosphate (10 mM), and sodium orthovanadate (1 mM)]. Before
lysis in 250 mL buffer on ice for 5 minutes, cells were washed twice with ice-cold PBS. Protein extracts were cleared by centrifugation
for 10 minutes at 20,000 x g at 4C and transferred into fresh tube. Protein concentration was measured using Pierce BCA Protein
Assay kit according to manufacturer’s instructions (Thermo Fisher Scientific, Waltham, MA, USA). 20 mg of total protein/lane were
separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) using NuPAGE 4%–12% Bis-Tris SDS-PAGE Protein Gels
(Thermo Fisher Scientific), and western blot was completed using the Bolt Mini Blot Module (Thermo Fisher Scientific) according
to the manufacturer’s instructions. After transfer and blocking of polyvinylidene fluoride (PVDF) membranes (Immobilon) in 5%
BSA TBS Tween-20 buffer (Thermo Fisher Scientific), primary antibody directed against FADS2 (PA5-87765; RRID: AB_2804393,
Thermo Fisher Scientific) was applied overnight at 4C at a dilution of 1:1000 followed by probing with the appropriate Odyssey fluo-
rophore-labeled secondary antibody and visualization on the Li-CorOdyssey imaging system (LI-COR Biotechnology, NE, USA).
Protein expression levels were quantified using Image Studio Lite (LI-COR Biotechnology), normalized relative to the indicated
housekeeping protein, and expressed as fold-changes relative to the control treatment.
Lipid extraction
Cell and homogenized tissue lipids were extracted using methods similar to those described by Matyash et al., 2008 and were quan-
tifiable through the use of internal standards in the form of deuterated lipids (SPLASH Lipid-o-mix, Avanti Polar Lipids, Alabaster,
USA) and an odd-chain fatty acid found to be not present within the samples (nonadecanoic acid, Sigma Aldrich, Munich, Germany).
To minimize pipetting error, a stock internal standard solution was made in bulk using 720 mL MTBE (0.01% BHT), 40 mL SPLASH
Lipid-o-mix and 20 mL nonadecanoic acid in MTBE (3.35 mM) per 2 M cells. Cell pellets in 2 mL clear glass vials (2M cells)
were twice washed with PBS solution, before adding 220 mL of methanol and 780 mL of the prepared internal standard stock solution.
Capped vials were vortexed for 20 s, before 1.5 h bench-top agitation. Phase separation was induced by adding 200 mL of aqueous
ammonium acetate (150 mM) before samples were vortexed for 20 s and centrifuged for 5 min at 2,000 x g. The organic supernatant




100 mL of the lipid extract was dried under nitrogen gas in 4 mL glass vials. Fatty acids were hydrolysed from lipids using 1:1 meth-
anol:tetrabutylammonium hydroxide (40 wt. % in water) and heating at 85C for 2 h before allowing to cool to room temperature.
1.5 mL of water (Optima) was added to each of the vials and acidified with 120 mL of 5 M aqueous hydrochloric acid to achieve
a pH of 2. Biphasic extraction of the supernatant was then undertaken using two separate aliquots (1 mL) of n-hexane to optimize
the recovery of fatty acids. The individual sample supernatant fractions were combined and dried under nitrogen to yield fatty acids.
The obtained fatty acids were then functionalisedwith AMPP+ using an AMP+Mass Spectrometry Kit (CaymanChemical, Ann Arbor,
MI) and following a similar method discussed by Bollinger et al. (2010). Briefly, 150 mL of 4:1 ACN:DMF was added to the hydrolysed
lipid samples prepared above, followed by 10 mL of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCdHCl; 1 M in water), 20 mL
of 1-hydroxybenzotriazole (5 mM in 99:1 ACN:DMF), and 20 mL of AMPP+ coupling reagent (15 mM in ACN). The resulting solution
was sealed, vortexed for 1 min and heated at 65C for 30 min. After cooling to room temperature, the reaction mixtures were diluted
with water (1 mL) and saturated aqueous NH4Cl (50 mL); mixtures were then twice extracted using MTBE (2 3 1 mL). The MTBE
supernatants were combined and stored in sealed 2 mL vials at 20C before MS analysis. 5 mL of the Restek 37 mix of FAMEs
and blanks were also derivatised through the above method and were used as experimental quality-controls.
Gas chromatography – pooled fatty acyl analysis
A reference standard of 38 fatty acid methyl ester standards was prepared by mixing a purchased 37 fatty acid methyl ester (FAME)
standard (Restek, Bellefonte, PA, USA) and 450 mM methyl-nonadecanoate in MTBE (Sigma Aldrich) at a 1:9 ratio. Samples were
prepared for analysis by mixing sample extracted lipids 5:1 with TMSH. Pooled batch quality controls (PBQC) and blanks were
used throughout for quality control and data reliability.
Samples were analyzed using a TQ8040 GC/MS (Shimadzu, Kyoto, Japan) with chromatographic separation being carried out
through an RTX-2330 capillary column (cyanopropyl stationary phase, 60 m x 0.25 mm, 0.20 mm film thickness; Restek). GC/MS in-
strument conditions were then optimized for FAME separation (He carrier gas, column flow of 2.6mL/min, 22:1 split ratio, 1 mL sample
injections, injector temperature of 220C, interface and ion source temperature of 250C). To shorten the total experiment duration
and assist with chromatographic separation, a 30-minute column oven temperature gradient was used (150C initial temperaturewith
a 10C/min increase to 170C, followed by a 2C/min increase to 200C and a further 1.3C/min increase to 211C where the tem-
perature was held for the remaining 5 minutes of the experiment). Column eluents were then subject to 70 eV of source energy for
electron ionisation and ions were detected by Q3 scan mode over a m/z 50-650 range.
MALDI-MSI OzID for lipid double bond imaging
10 mm tissue sections mounted on standard glass slides were first thinly coated with 12 passes (45 mm spray height, 30C,
10 psi, 2 mm track spacing) of 100 mM sodium acetate (2:1 methanol/chloroform) via an HTX TM-Sprayer (HTXImaging, Chapel
Hill, NC, USA). Sample slides were then coated with 2,5-DHA via sublimation (40 mg, 160C, 4 minutes) using a sublimator
(HTXImaging, Chapel Hill, NC, USA). Coated sample slides were then loaded into a prototype mMALDI source (Barré et al.,
2019) (Nd:YAG laser operating at 1.5 kHz, producing 25 nJ pulses at 355 nm; Waters, Wilmslow, England) for sample desorption
and ionisation. 50 mm2 pixels were sampled at a velocity of 2.0 mm/s with a 1.62 A laser diode current. Samples were analyzed
using a Synapt G2-Si HDMS mass spectrometer (Waters, Wilmslow, England) modified with a closed loop ozone generation sys-
tem to deliver ozone (up to 18% w/w in oxygen) to the ion mobility gas inlet of the instrument, as described previously (Poad
et al., 2017). Ozone was generated from oxygen feed gas (99.999% purity, Linde Gas Benelux BV, the Netherlands) using a
high concentration ozone generator (TG-40 gen 2, Ozone Solutions, Hull, IA, USA) and the concentration measured online using
a UV-absorption based ozone monitor (106-H, 2B Technologies, Boulder, CO). The mass spectrometer was operated in ion-
mobility mode, resulting in a reaction time with ozone of 15 ms, corresponding to the ion-mobility drift time. The quadrupole
mass filter was set to transmit m/z 782 (i.e., [PC 34:1+Na]+ and [PC 36:4+H]+) which was subsequently allowed to react with
ozone in the ion mobility cell to yield OzID fragmentation. The resulting monoisotopic ions (precursors and products) were
then mass analyzed by time of flight (nominal resolution 15,000).
Direct infusion ESI-OzID of lipid double bonds
The DBs of intact glycerophospholipids were determined viamass spectrometry using amodified Orbitrap Elite high-resolutionmass
spectrometer (Thermo Scientific, Bremen, Germany) capable of ozone-induced dissociation. Briefly, ozone was produced via a high-
concentration generator (Titan-30UHC Absolute Ozone, Edmonton, Canada) and was introduced into the helium buffer gas flow
before conduction through to the high-pressure region of the linear ion trap (LIT) (Paine et al., 2018). Similarly, a diverter valve
was placed on the nitrogen gas inlet to the higher collisional dissociation (HCD) cell, and nitrogen was replaced with generated ozone
gas (Marshall et al., 2019).
Operating in positive-ion mode for PC lipid OzID, cell line lipid extract samples were mixed 1:1 (v/v) with 500 mM methanolic
sodium acetate solution and introduced to the mass spectrometer via a chip-based nano-electrospray source (TriVersa Nano-
mate, Advion, Ithaca, NY, USA) using 1.35 kV/0.35 psi spray parameters. Using the Thermo Xcalibur software package, a data
independent acquisition sequence was created to perform sequential OzID (activation time (AT) = 2 s (HCD), collision energy
(CE) = 1 V) and CID/OzID (MS2: AT = 30 ms (LIT), normalized collision energy (NCE) = 40; MS3: AT = 1 s, NCE = 0) for 9 sodiatedCell Reports 34, 108738, February 9, 2021 e6
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175-1000 Da scan range. Included sodiated precursor ion m/z values were: 754.6, 780.6, 782.6, 804.6, 806.6, 808.6, 810.6,
830.6 and 832.6. This method was also used to assign DBs within lipids that were labeled with stable-isotope fatty acids, with
the only method modification being the precursor ion masses that were selected. For PCs labeled with heavy-palmitate or
heavy-stearate three labeled and three unlabeled lipids were submitted for OzID and CID/OzID analysis (m/z 754, 770, 782,
798, 810 and 826; and m/z 754, 772, 782, 800, 810 and 826, respectively). The product ions from all fragmentation experiments
were detected using the orbitrap mass analyzer for high resolution and accurate mass, allowing for unambiguous assignment of
characteristic fragments to specific lipids and not isobaric lipids or isotopes. Intensity values obtained from OzID and CID/OzID
mass spectrometric experiments were the average of 24 and 39 scans, respectively. Adapting the work of Marshall et al.
(2016) and Hancock et al. (2019) and the aforementioned positive-ion mode experiments, MS3 experiments were created for
TG and CE related scans, respectively (cf. Table S4). In brief, for TGs, sodiated precursor ions were mass selected and underwent
activated OzID in the linear ion trap (MS2: NCE = 27, AT = 2 s), with subsequent monounsaturated fatty acid related product ions
undergoing OzID in the HCD cell (MS3: CE = 1 V, AT = 5 s) before high resolution detection. For CEs, precursor ions first underwent
activated OzID in the linear ion trap (MS2: NCE = 2, AT = 500 ms) before the [M+Na+16]+ product ion was mass selected to un-
dergo further activated OzID and detection in the linear ion trap (MS3: NCE = 1, AT = 5 s).
Operating in negative-ion mode for PE, PS, PG and PI lipid OzID, cell line lipid extract samples were mixed 1:1 (v/v) with 5 mM
methanolic ammonium acetate solution and introduced to the mass spectrometer via a TriVersa Nanomate, set to use
1.35 kV/0.35 psi spray parameters. Using the Thermo Xcalibur software package, 4 separate data independent acquisition
sequences were created for each of the phospholipid subclasses. For each method, sequential OzID (AT = 2.5 s (HCD), CE =
1 V) and CID (MS2: AT = 5 ms (LIT), NCE = 33-39) was performed for 9 deprotonated lipid precursor masses (totalling 36 phos-
pholipids) with a maximum injection time of 100 ms, isolation window of ± 0.5 Da across a scan range of 200-1000 Da. Included
deprotonated precursor ion m/z values were: (for PE) 688.5, 716.5, 742.5, 744.5, 782.5,766.5, 768.5, 770.5 and 772.5; (for PS)
732.5, 760.5, 786.5, 788.5, 806.5, 810.5, 812.5, 814.5 and 816.5; (for PG) 719.5, 747.5, 773.5, 775.5, 793.5, 797.5, 799.5,
801.5 and 803.5; and (for PI) 807.5, 835.5, 861.5, 863.5, 885.5, 887.5, 889.5, 891.5 and 915.5. The product ions from all fragmen-
tation experiments were detected using the orbitrap mass analyzer for high-resolution mass accuracy (120,000 FWHM at 400 m/z),
allowing for unambiguous assignment of characteristic fragments to specific lipids and not isobaric lipids or isotopes. Intensity
values obtained from OzID and CID mass spectrometric experiments were averaged across 16 and 77 scans individual scans,
respectively.
Usingmethods similar to those developed for cell line extracts, OzIDwas also performed on homogenized tissue lipid extracts. Due
to the small quantity of tissue from which lipids were extracted, extracts were first dried under nitrogen gas and reconstituted to one
quarter the volume (4-fold increase in concentration). Samples were reconstituted in either methanolic sodium acetate (500 mM) for
positive-ion mode or methanolic ammonium acetate (5 mM) for negative-ion mode. Using the parameters described previously for
positive-ion mode PC acquisitions, OzID and CID/OzID was performed on three PC lipids (m/z 754.5, 782.6 and 810.6). Resulting
OzID and CID/OzID data was detected using the orbitrap mass analyzer (120,000 FWHM at 400 m/z) and ion intensity values
were averaged across 11 and 23 scans, respectively. Given the low sample concentration and the decrease in ion detection effi-
ciency inherent to negative-ion mode mass spectrometry, the aforementioned method to obtain OzID DB data for PE, PS, PG
and PI lipids was modified. A data independent method was created to sequentially acquire OzID (AT = 10 s; NCE = 19-23) for
the 32:1, 34:1 and 36:1 phospholipid compositions (12 total phospholipids) using a maximum injection time of 100 ms, isolation win-
dow of ± 0.5 Da across a scan range of 200-1000 Da. Included m/z values were: 688.5, 716.5, 719.5, 732.5, 744.5, 747.5, 760.5,
775.5, 788.5, 807.5, 835.5 and 863.5. To further improve detection of low intensity signals, product ion fragments were analyzed
in the high-pressure region of the dual linear ion trap. Low resolution ion fragments were compared against standards run under
the same conditions to improve reliability of assignments. Intensity values obtained from OzID experiments were averaged across
9 scans.
Direct infusion ESI-OzID of pooled fatty acid double bonds (AMPP+ derivatization)
Hydrolysed lipid extracts (including cell line lipids, LNCaP siRNA experiments and the fatty acid methyl ester standard mix) were de-
rivatised with AMPP+ as described above (refer to method ‘‘AMPP derivatisation’’) and introduced via chip-based nano-electrospray
using 1.90 kV/0.5 psi spray parameters. Using the Thermo Xcalibur software package, data independent acquisition sequences were
created to perform ozonolysis within the linear ion trap (AT = 5 s, NCE = 25) for 24 fatty acid precursor ion masses with a maximum
injection time of 100 ms, isolation window of ± 0.5 Da and scan range between 105-600 Da. Included precursor ion masses
for AMPP+ derivatised FAs were: 14:1 (m/z 393.5), 14:2 (m/z 391.5), 15:1 (m/z 407.5), 16:1 (m/z 421.5), 16:2 (m/z 419.5), 16:3
(m/z 417.5), 17:1 (m/z 435.5), 18:1 (m/z 449.5), 18:2 (m/z 447.5), 18:3 (m/z 445.5), 19:1 (m/z 463.5), 20:1 (m/z 477.5), 20:2
(m/z 475.5), 20:3 (m/z 473.5), 20:4 (m/z 471.5), 20:5 (m/z 469.5), 20:6 (m/z 467.5), 22:1 (m/z 505.5), 22:2 (m/z 503.5),
22:3 (m/z 501.5), 22:4 (m/z 499.5), 22:5 (m/z 497.5), 22:6 (m/z 495.5) and 24:1 (m/z 533.5). Subsequent OzID product ions were
then transferred through to the orbitrap mass analyzer for unambiguous assignment by high-resolution mass detection (mass res-
olution 120,000 (FWHM) at m/z 400). Ion abundance values were averaged across 11 scans.e7 Cell Reports 34, 108738, February 9, 2021
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Lipid extracts from cell lines were run through an automated lipidomics workflow using an LC-20A HPLC (Shimadzu, Kyoto, Japan)
set to deliver 100 mL sample loop-injections into a mobile phase of 5 mM methanolic ammonium acetate flowing at 15 mL/min. The
sample column and column oven were bypassed with Viper PEEKsil (50 mm, Thermo Fisher, Waltham, MA, USA) to maintain instru-
ment back pressure limits. Sample lipids were then directly infused through the electrospray ionisation source of a QTRAP 6500
hybrid triple quadrupole/LIT mass spectrometer (SCIEX, Concord, ON, Canada) using a spray voltage of 5 kV, a source temperature
of 150C and both source gasses set to 15 (arb.). Various precursor ion and neutral loss scans were employed to confirm lipid head
group, with the detectedm/z being indicative of summed-fatty-acyl composition. (PC: PISm/z 184.2, CE: 39V; PE: NLm/z 141.1, CE:
29V; PS: NL m/z 185.1, CE: 29V; PG: NL m/z 189.1, CE: 29V; PI: NL m/z 275.1, CE: 29V; ChE: NL m/z 259.1, CE: 29V). Instrument
blanks were run through-out to ensure no sample carry-over and pooled batch quality controls (PBQC) were used to gauge instru-
ment performance over the duration of the experiment.
QUANTIFICATION AND STATISTICAL ANALYSIS
Gas chromatography – pooled fatty acyl analysis
Tabulated ion intensity data from the m/z 55 extracted ion chromatogram (XIC) was extracted from the data files using the native
Shimadzu Post-run analysis software. The m/z 55 XIC was chosen due to the enhanced detection of monounsaturated fatty acids.
To ensure detection biasing was minimal, 3-point calibration curved were created with the reference standard to obtain molar
correction factors for all fatty acid species. Using a Python script that was developed inhouse, chromatographic peaks were
compared with a temporal tolerance of 0.013 min against the reference standard for fatty acyl species assignment. For quantifi-
cation, the slope of the peak and the maximum height (min. threshold: 0.01% of total ions) was used to fit a Gaussian distribution,
which was subsequently integrated and normalized to the methyl-nonadecanoate internal standard. Previous analysis of the sam-
ples without an included internal standard revealed no detectable methyl-nonadecanoate and hence all integrated chromato-
graphic signal was attributed to the internal standard. Pandas DataFrames were then created and exported to .csv format where
Microsoft Excel was then used for the remaining cell count normalization, internal standard concentration factoring, statistical
analysis, and graphing.
MALDI-MSI OzID for lipid double bond imaging
HDI software (Version 1.4, Waters, Wilmslow, England) was used for data processing and image creation by integrating positional
files obtained from the mMALDI source with theWaters .raw files from the Synapt G2-Si. The top 200most intense fragment ion peaks
were extracted from the raw/un-normalized spectra across a mass range of 200-1000 m/z with an isolation window of 0.02 Da and
mass resolution set to maximum (20,000). Characteristic ions for the OzID aldehyde and Criegee ions were identified and summed to
show isomeric distribution of PC 34:1. Similarly for PC 36:4n-6, aldehyde and Criegee ions from each double bond position were
summed to show the distribution across tissue. Because quantitation was not the focus of the imaging analysis, maximum gradient
intensity values were individually set to assist visualization and contrast of lipid distributions. Hence, the maximum gradient values
vary for each lipid species and can be observed in the linear color scale bars of Figure S1. Images were smoothed using linear inter-
polation and composite images were created using the in-built ‘‘Add’’ data blending mode, which blends co-localized colors
together.
Direct infusion ESI-OzID of lipid double bonds and pooled fatty acid double bonds (AMPP+)
Averagedmass spectral datawere extracted from the Thermo .raw files using Thermo Xcalibur Qual Browser (Version 3.0.63, Thermo
Scientific, Bremen, Germany). Data tables were imported to Microsoft Excel where the data was normalized to the total ion count
(TIC) before product ions were located and quantified. For high resolution mass spectrometry, a minimum peak intensity threshold
of 0.013% of the TIC (10:1 signal-to-noise) was put in place, and am/z Dppm of 6 was used for product ion assignment validation.
Translation to assignments was made according to previously published tables for OzID aldehyde and Criegee product ion neutral
loss masses (Paine et al., 2018) OzID aldehyde and Criegee ion abundances were summed and represented as a fraction of the all
isomer related OzID product ion signals (i.e., fractional distribution). This method of representation provides a further degree of
normalization for comparison, making the fractions reflective of changes in the molar concentration of isomers.
Conventional lipidomics for phospholipid profiles
Lipidview (Version 1.3 beta, SCIEX, Concord, ON, Canada) was used for data processing of SCIEX data files obtained from the
QTRAP 6500. Lipid assignments were based on the software lipid tables and shortlisted to include even-chain lipids with 0-6 s.
Odd-chain/ether-lipid data was obtained but was not included in this study due to the ambiguity in assigning isobars in low resolution
mass spectrometry. Isotope correction factors were applied, and MS peaks were ratioed to the isotope corrected internal standard
included in each scan type. The inclusion of deuterated and odd chain fatty acids within the internal standard lipids sufficiently mass
shifted internal standards away from any biological lipids, therefore allowing accurate and reliable peak intensity measurements to be
discerned. Data tables were extracted from Lipidview and imported to Microsoft Excel for cell count normalization, internal standard
concentration factoring, statistical analysis, and graphing.Cell Reports 34, 108738, February 9, 2021 e8
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The mean with 95% confidence intervals was used for error analysis on column-charts throughout and was calculated using Micro-
soft Excel and conventional equations. Box and whisker plots display conventionally accepted quartile values for the data minimum,
1st quartile, median, 3rd quartile andmaximum. For Figures 1B and 1C, the mean and variance were calculated using Microsoft Excel
to establish an independent one-tailed Welsh’s t test and t-values were translated to statistical significance via relevant degrees of
freedom and critical t-value tables. Remaining principal component analyses, heatmaps, and correlation matrices, including statis-
tical significance and correlation coefficients, were calculated using R x64 3.6.1 packages and built-in functions using a Pearson
product-moment correlation (i.e., PerformanceAnalytics, prcomp(), Hmisc() and corrplot()). With the exception of Figure 6, all
population values (i.e., ‘‘n=’’) refer to cell culture replicates. The population values of Figure 6 instead refer to either the number of
cell culture replicates, or the number of patient tissues used to conduct the statistical test, as indicated in the figure caption. Specific
statistical details for each of the figures (including number of replicates, p value representation and error model), can be found within
the respective figure captions.e9 Cell Reports 34, 108738, February 9, 2021
